logo
SeraCare is part of LGC Clinical Diagnostics - Learn More
HOME
Reference Materials for the Development of Assays for the Detection of Measurable Residual Disease in Acute Myeloid Leukemia

The detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) can present a challenge because it can require detecting just several malignant cells within thousands – if not millions – of normal cells. One of the major challenges associated with the development and validation of assays for MRD in AML is the absence of cell-based reference materials that feature diverse mutations that may be encountered clinically. 

In this scientific poster, SeraCare's scientific experts begin to address the need for standards by developing a  full process cell-based reference materials.  

To download, fill out the form and you will receive an email with the content.

AACR 2023 SP - Reference Materials for the Development of Assays for the Detection of Mesurable Residual Disease in Acute Myeloid Leukemia
Scroll to top